Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

$4.20 ▲ +0.04 (+0.96%)

As of May 20, 2026 04:00 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001593899

Market Cap 332.63 Mn

P/E -1.99

Div. Yield 0.00

ROIC (Qtr) -0.01

Add ratio to table...

About

Atea Pharmaceuticals, Inc. is a late stage clinical biopharmaceutical company focused on discovering developing and commercializing novel orally administered antivirals to treat serious viral diseases. The company leverages its deep understanding of antiviral drug development medicinal chemistry biochemistry and virology to build a proprietary platform of nucleosides and nucleotides. This platform has yielded bemnifosbuvir a double prodrug nucleotide analog and AT 587 another novel double prodrug nucleotide analog. Bemnifosbuvir is being developed...

Atea Pharmaceuticals, Inc. is a late stage clinical biopharmaceutical company focused on discovering developing and commercializing novel orally administered antivirals to treat serious viral diseases. The company leverages its deep understanding of antiviral drug development medicinal chemistry biochemistry and virology to build a proprietary platform of nucleosides and nucleotides. This platform has yielded bemnifosbuvir a double prodrug nucleotide analog and AT 587 another novel double prodrug nucleotide analog. Bemnifosbuvir is being developed in combination with ruzasvir for the treatment of hepatitis C virus while AT 587 is being advanced as a potential first direct acting antiviral for hepatitis E virus infection particularly in immunocompromised patient populations. For hepatitis C virus the bemnifosbuvir and ruzasvir combination is undergoing global Phase 3 clinical evaluation with the C BEYOND trial in the United States and Canada and the C FORWARD trial in regions outside of North America. The company anticipates submitting a new drug application to the US Food and Drug Administration in March 2027 contingent upon successful results from these Phase 3 studies.

Atea Pharmaceuticals, Inc. does not currently generate revenue from product sales as all its therapeutic candidates remain in clinical development and have not yet received regulatory approval for commercial sale. The company has no approved products on the market and therefore reports zero product revenue in its financial operations. Research and development activities represent the primary focus of the company's resource allocation including clinical trials for bemnifosbuvir and ruzasvir in hepatitis C virus infection and AT 587 for hepatitis E virus infection. Funding for these efforts is obtained through capital markets transactions to support the advancement of its antiviral pipeline toward potential regulatory approval and future commercialization.

Atea Pharmaceuticals, Inc. operates in the competitive antiviral therapeutics sector with a specific focus on hepatitis virus infections. In the hepatitis C virus treatment landscape the company faces established competitors including Gilead Sciences with its Epclusa regimen of sofosbuvir and velpatasvir and AbbVie with its Mavyret regimen of glecaprevir and pibrentasvir. Additional competitors include Merck's Zepatier combining elbasvir and grazoprevir and Gilead's Sovaldi as a foundational component in combination therapies. These current standards of care dominate the market having generated over two point five billion dollars in global net sales in 2025 with the United States accounting for approximately half of this total. Atea differentiates its bemnifosbuvir and ruzasvir regimen through its protease inhibitor free mechanism which avoids the drug interaction risks associated with protease inhibitor based therapies. The regimen is designed for a duration of eight weeks in non cirrhotic patients offering a shorter course than many existing twelve week regimens while maintaining pan genotypic efficacy across all hepatitis C virus genotypes. Preclinical and clinical data indicate a low risk of drug drug interactions with commonly prescribed medications such as proton pump inhibitors enhancing patient convenience and simplifying co medication management. In the hepatitis E virus space where no direct acting antiviral therapies are currently approved Atea aims to position AT 587 as a first in class treatment addressing significant unmet medical need. Hepatitis E virus infection poses a serious threat in immunocompromised populations including solid organ transplant recipients where it can rapidly progress to cirrhosis and liver failure. Current off label treatment with ribavirin is limited by significant side effects including anemia and teratogenic effects creating a clear opportunity for a novel direct acting antiviral. Atea's approach leverages its nucleoside nucleotide platform which builds on the proven success of similar mechanisms in treating human immunodeficiency virus hepatitis B virus and hepatitis C virus infections.

As a pre revenue company with no approved products Atea Pharmaceuticals, Inc. does not currently serve paying customers. However its target patient populations for potential future commercialization are clearly defined based on epidemiological data and medical need. For hepatitis C virus infection the World Health Organization estimates that approximately fifty million people globally live with chronic infection with about one million new infections occurring annually. In the United States the Centers for Disease Control and Prevention reports that as many as four million persons are infected with hepatitis C virus. The company focuses on non cirrhotic patients particularly those between twenty and forty nine years of age who represent a significant portion of the hepatitis C virus infected population. Additionally the company addresses patients with compensated cirrhosis who may benefit from an extended twelve week treatment duration as evaluated in its ongoing Phase 3 trials. For hepatitis E virus infection the filing cites an estimated nineteen point five million acute infections each year globally. Chronic hepatitis E virus infection develops in roughly three percent of immunocompromised individuals creating a substantial at risk population estimated at thirteen thousand five hundred cases annually in the United States and Europe based on solid organ and stem cell transplant statistics. The company specifically targets solid organ and stem cell transplant recipients people living with human immunodeficiency virus and those with hematologic or rheumatic conditions where hepatitis E virus can cause rapid progression to liver cirrhosis. In these populations current treatment options are limited to reducing immunosuppression which risks transplant rejection or off label ribavirin therapy associated with side effects such as dose dependent anemia dry cough teratogenic effects and dermatologic reactions. Upon achieving regulatory approval Atea anticipates that its therapies would be prescribed by specialists including hepatologists infectious disease specialists and transplant physicians. The medications would be distributed through specialty pharmacy networks and integrated into healthcare systems serving these patient communities to ensure appropriate access and follow up care.

Investment thesis

Bull case

Atea’s Phase III strategy for HCV is a textbook example of a value‑unlocking milestone that the market has not yet fully priced in, given the company’s disciplined cash discipline and clear pathway to regulatory approval. The firm’s $329 million cash balance extends beyond the next clinical hurdle into 2027, providing the runway to navigate both the North American and global enrollment components without the immediate need for external financing. By positioning its regimen as a best‑in‑class, eight‑week cure for non‑cirrhotic patients, the company taps a sizable portion of the $3 billion HCV treatment market that prefers short‑duration, low‑side‑effect options, potentially capturing a large share of prescriber preference. The fixed‑dose combination that is bioavailable with or without food and unaffected by proton pump inhibitors directly addresses a major adherence barrier, thereby differentiating it from the incumbent sofosbuvir/velpatasvir therapy that suffers from drug‑drug interactions with acid‑reducing agents. The company’s Phase II data, achieving a 98 % SVR12 across multiple genotypes, reinforce the likelihood of a positive Phase III readout, as historical data show strong predictive value for HCV trials. The announcement of a share repurchase program that retired 7.6 million shares at an average price of $3.26 demonstrates management’s confidence that the stock is undervalued and creates a more attractive valuation for new investors. Atea’s dual‑mechanism of action for bemifovir, validated through kinetic modeling and in vitro studies, positions the drug as potentially more resilient to resistance mutations, a critical selling point in the era of emerging NS5A resistance. The company’s expansion into hepatitis E, an orphan disease lacking approved therapies, opens an additional revenue stream projected at $500–$750 million per year if an orphan designation and pricing model comparable to ribavirin are secured. The combined pipeline strategy places Atea on a trajectory to secure multiple regulatory approvals and revenue streams while maintaining a strong balance sheet, providing significant upside if Phase III outcomes meet or exceed expectations.
Atea’s emphasis on the unique dual mechanism of action for bemifovir is more than a marketing point; it suggests a robust antiviral activity that could translate into higher cure rates, especially in populations with resistance mutations. The company’s ability to maintain a high SVR12 rate in patients with NS5A resistant variants at baseline implies a lower risk of virologic failure, thereby potentially improving market adoption among clinicians seeking reliable treatment options. This differentiation may also allow Atea to command a premium pricing strategy, especially if the drug proves effective in the challenging cirrhotic patient subset, which typically drives higher treatment costs. The company’s clear focus on a single, high‑profile asset mitigates dilution risk from portfolio over‑extension, preserving resources for the critical Phase III readout and future product development. The projected Phase I initiation for two hepatitis E candidates in 2026 further diversifies Atea’s pipeline, enabling the company to leverage its nucleotide platform across multiple viral targets. The orphan drug pathway could provide both market exclusivity and financial incentives such as tax credits, which would offset development costs and enhance profitability. These factors collectively suggest that the market is undervaluing the company’s strategic position and potential for multiple product approvals.
The company’s transparent reporting of a strong cash runway through 2027, coupled with its commitment to a disciplined capital allocation strategy, reduces the likelihood of financing disruptions that could derail the Phase III program. Atea’s prior experience with multi‑country enrollment and its established data on patient adherence reinforce the feasibility of achieving timely enrollment targets for both CBEYOND and C FORWARD trials. The alignment of the trial designs with the prevailing global standard of care (Epclusa) ensures that the company’s data will be directly comparable to the current market leader, facilitating regulatory and payer acceptance. By focusing on a fixed‑dose combination, Atea removes a significant compliance barrier that often plagues multi‑drug regimens, thereby enhancing real‑world effectiveness and encouraging uptake by prescribers. The company's clear communication about no PPI interaction, a frequent concern for chronic HCV patients, positions the drug as a convenient option for a large segment of the patient population, potentially accelerating adoption. The Phase II data’s strong safety profile also reduces regulatory risk and may shorten the path to approval if Phase III confirms efficacy. The company's commitment to continuous data presentation at scientific meetings demonstrates an ongoing effort to build clinical credibility and generate market interest. Combined, these factors support a bullish view that the market has not yet captured the full upside of Atea’s clinical and financial positioning.
Atea’s strategic emphasis on a streamlined product portfolio and a single, highly differentiated HCV therapy provides the company with a clear narrative for investors, which is often a key driver in valuation multiples. The company’s proactive approach to addressing drug‑drug interactions and its focus on patient adherence align with payer and clinician demands for simplified, effective regimens, potentially enhancing market penetration. The ability to capture the orphan market for hepatitis E provides a high‑margin, low‑volume revenue stream that can offset the capital intensity of the HCV program, improving the overall risk‑reward profile. The strong cash position also affords the flexibility to navigate regulatory challenges, engage in partnership or licensing deals if needed, and maintain operational continuity. These elements combine to suggest a high probability of success for the Phase III program, with the added benefit of future revenue diversification from hepatitis E. The current share price appears to be below intrinsic value based on these catalysts, indicating potential upside for shareholders.
Atea’s use of the proprietary nucleotide platform across both HCV and hepatitis E allows for platform synergies that can reduce development costs and accelerate product timelines. The company’s data demonstrating a 200‑fold higher antiviral activity of its hepatitis E candidates versus ribavirin suggests a clear therapeutic advantage over the only off‑label option currently used, potentially creating a first‑in‑class drug that could quickly become the standard of care for immunocompromised patients. The projected orphan market value of $500–$750 million per year further underscores the potential profitability of the hepatitis E program. Coupled with the strong Phase III pipeline for HCV, Atea’s diversified pipeline positions it well for sustained growth, reducing reliance on a single product’s success. This diversified approach enhances the company’s resilience against market or regulatory setbacks, supporting a bullish outlook.

Atea’s Phase III strategy for HCV is a textbook example of a value‑unlocking milestone that the market has not yet fully priced in, given the company’s disciplined cash discipline and clear pathway to regulatory approval. The firm’s $329 million cash balance extends beyond the next clinical hurdle into 2027, providing the runway to navigate both the North American and global enrollment components without the immediate need for external financing. By positioning its regimen as a best‑in‑class, eight‑week cure for non‑cirrhotic patients, the company taps a sizable portion of the $3 billion HCV treatment market that prefers short‑duration, low‑side‑effect options, potentially capturing a large share of prescriber preference. The fixed‑dose combination that is bioavailable with or without food and unaffected by proton pump inhibitors directly addresses a major adherence barrier, thereby differentiating it from the incumbent sofosbuvir/velpatasvir therapy that suffers from drug‑drug interactions with acid‑reducing agents. The company’s Phase II data, achieving a 98 % SVR12 across multiple genotypes, reinforce the likelihood of a positive Phase III readout, as historical data show strong predictive value for HCV trials. The announcement of a share repurchase program that retired 7.6 million shares at an average price of $3.26 demonstrates management’s confidence that the stock is undervalued and creates a more attractive valuation for new investors. Atea’s dual‑mechanism of action for bemifovir, validated through kinetic modeling and in vitro studies, positions the drug as potentially more resilient to resistance mutations, a critical selling point in the era of emerging NS5A resistance. The company’s expansion into hepatitis E, an orphan disease lacking approved therapies, opens an additional revenue stream projected at $500–$750 million per year if an orphan designation and pricing model comparable to ribavirin are secured. The combined pipeline strategy places Atea on a trajectory to secure multiple regulatory approvals and revenue streams while maintaining a strong balance sheet, providing significant upside if Phase III outcomes meet or exceed expectations.
Atea’s emphasis on the unique dual mechanism of action for bemifovir is more than a marketing point; it suggests a robust antiviral activity that could translate into higher cure rates, especially in populations with resistance mutations. The company’s ability to maintain a high SVR12 rate in patients with NS5A resistant variants at baseline implies a lower risk of virologic failure, thereby potentially improving market adoption among clinicians seeking reliable treatment options. This differentiation may also allow Atea to command a premium pricing strategy, especially if the drug proves effective in the challenging cirrhotic patient subset, which typically drives higher treatment costs. The company’s clear focus on a single, high‑profile asset mitigates dilution risk from portfolio over‑extension, preserving resources for the critical Phase III readout and future product development. The projected Phase I initiation for two hepatitis E candidates in 2026 further diversifies Atea’s pipeline, enabling the company to leverage its nucleotide platform across multiple viral targets. The orphan drug pathway could provide both market exclusivity and financial incentives such as tax credits, which would offset development costs and enhance profitability. These factors collectively suggest that the market is undervaluing the company’s strategic position and potential for multiple product approvals.
The company’s transparent reporting of a strong cash runway through 2027, coupled with its commitment to a disciplined capital allocation strategy, reduces the likelihood of financing disruptions that could derail the Phase III program. Atea’s prior experience with multi‑country enrollment and its established data on patient adherence reinforce the feasibility of achieving timely enrollment targets for both CBEYOND and C FORWARD trials. The alignment of the trial designs with the prevailing global standard of care (Epclusa) ensures that the company’s data will be directly comparable to the current market leader, facilitating regulatory and payer acceptance. By focusing on a fixed‑dose combination, Atea removes a significant compliance barrier that often plagues multi‑drug regimens, thereby enhancing real‑world effectiveness and encouraging uptake by prescribers. The company's clear communication about no PPI interaction, a frequent concern for chronic HCV patients, positions the drug as a convenient option for a large segment of the patient population, potentially accelerating adoption. The Phase II data’s strong safety profile also reduces regulatory risk and may shorten the path to approval if Phase III confirms efficacy. The company's commitment to continuous data presentation at scientific meetings demonstrates an ongoing effort to build clinical credibility and generate market interest. Combined, these factors support a bullish view that the market has not yet captured the full upside of Atea’s clinical and financial positioning.
Atea’s strategic emphasis on a streamlined product portfolio and a single, highly differentiated HCV therapy provides the company with a clear narrative for investors, which is often a key driver in valuation multiples. The company’s proactive approach to addressing drug‑drug interactions and its focus on patient adherence align with payer and clinician demands for simplified, effective regimens, potentially enhancing market penetration. The ability to capture the orphan market for hepatitis E provides a high‑margin, low‑volume revenue stream that can offset the capital intensity of the HCV program, improving the overall risk‑reward profile. The strong cash position also affords the flexibility to navigate regulatory challenges, engage in partnership or licensing deals if needed, and maintain operational continuity. These elements combine to suggest a high probability of success for the Phase III program, with the added benefit of future revenue diversification from hepatitis E. The current share price appears to be below intrinsic value based on these catalysts, indicating potential upside for shareholders.
Atea’s use of the proprietary nucleotide platform across both HCV and hepatitis E allows for platform synergies that can reduce development costs and accelerate product timelines. The company’s data demonstrating a 200‑fold higher antiviral activity of its hepatitis E candidates versus ribavirin suggests a clear therapeutic advantage over the only off‑label option currently used, potentially creating a first‑in‑class drug that could quickly become the standard of care for immunocompromised patients. The projected orphan market value of $500–$750 million per year further underscores the potential profitability of the hepatitis E program. Coupled with the strong Phase III pipeline for HCV, Atea’s diversified pipeline positions it well for sustained growth, reducing reliance on a single product’s success. This diversified approach enhances the company’s resilience against market or regulatory setbacks, supporting a bullish outlook.

Bear case

While Atea’s Phase III program has reached enrollment milestones, the company still faces significant uncertainty surrounding the clinical outcome of its global trials, especially given the variable pharmacodynamics across different genotypes and the lack of head‑to‑head comparative data in a diverse patient population. The company’s reliance on a single therapeutic asset increases the concentration risk, as a negative readout would eliminate its most immediate revenue driver and potentially erode investor confidence. The high 98 % SVR12 in Phase II, although impressive, may not fully capture real‑world adherence challenges or the full spectrum of resistance mutations, leading to a potential overestimation of clinical success. The absence of any publicly disclosed safety data beyond Phase II raises questions about long‑term tolerability, which could delay regulatory approval or trigger post‑marketing restrictions. These factors collectively heighten the risk that the Phase III results will not meet market expectations, undermining the company’s valuation.
The company’s financial statements indicate an upward trend in R&D expenses that is likely to continue, and while the cash balance extends through 2027, the company has not disclosed a clear contingency plan for a delayed Phase III readout or for potential regulatory setbacks. The incremental capital requirements associated with both the HCV and hepatitis E programs could strain cash reserves if the company must extend trial timelines or undertake additional safety studies, potentially necessitating new debt or equity issuances that would dilute shareholders. The absence of a current strategic partner or licensing agreement for the HCV regimen raises the question of whether Atea will be able to secure favorable reimbursement terms or pricing in a highly competitive therapeutic landscape dominated by established payers and generics. A negative Phase III outcome could also impede the company’s ability to attract future investment for its hepatitis E pipeline, further compromising its growth prospects. The combined effect of these financial and strategic uncertainties warrants a bearish view.
The company's emphasis on the lack of proton pump inhibitor interaction, while a useful differentiation, may overstate the clinical relevance of this factor given that many patients on HCV therapy already receive alternative acid‑reducing agents that do not interact with sofosbuvir or other DAAs. The real‑world impact of this differentiation may be limited, especially if the drug’s overall cost remains higher than existing therapies. Additionally, the company’s data on drug‑drug interactions have not been corroborated by independent third‑party studies, raising questions about the robustness of these findings. Consequently, the perceived advantage over Epclusa may not translate into significant market capture, particularly if payers focus on efficacy and safety rather than a single pharmacokinetic interaction. This potential overvaluation of the differentiation may lead to a slower adoption curve, thereby reducing the company’s revenue potential and supporting a bearish outlook.
Atea’s hepatitis E program, while theoretically lucrative, remains at an early preclinical stage, and the company has not yet demonstrated a clear path to regulatory approval or market entry for these candidates. The projected $500–$750 million per year revenue estimate is based on orphan drug pricing assumptions that may not be realized in practice, as payers could negotiate lower prices or challenge the orphan designation. The company’s current data set of 200‑fold potency over ribavirin is promising but does not guarantee clinical efficacy or safety, and the company has not yet performed any in‑vivo efficacy studies or established a therapeutic index. This lack of translational data heightens the risk that the hepatitis E pipeline will not generate the projected revenue, weakening the company’s overall valuation.
The company’s current share repurchase program, although signaling confidence, was conducted at a relatively low average price, but this does not offset the broader concern that the stock may be trading at a premium relative to intrinsic value if the Phase III program fails. Moreover, the repurchase program’s impact on free cash flow is limited, given the magnitude of the company’s ongoing R&D spend. Investors may interpret the share buyback as a short‑term management tactic rather than a meaningful long‑term value creation strategy. If the company’s Phase III outcome does not result in regulatory approval, the share price may decline sharply, eroding the gains from the repurchase program and potentially triggering a broader market sell‑off. This scenario supports a bearish perspective on the stock’s future performance.

While Atea’s Phase III program has reached enrollment milestones, the company still faces significant uncertainty surrounding the clinical outcome of its global trials, especially given the variable pharmacodynamics across different genotypes and the lack of head‑to‑head comparative data in a diverse patient population. The company’s reliance on a single therapeutic asset increases the concentration risk, as a negative readout would eliminate its most immediate revenue driver and potentially erode investor confidence. The high 98 % SVR12 in Phase II, although impressive, may not fully capture real‑world adherence challenges or the full spectrum of resistance mutations, leading to a potential overestimation of clinical success. The absence of any publicly disclosed safety data beyond Phase II raises questions about long‑term tolerability, which could delay regulatory approval or trigger post‑marketing restrictions. These factors collectively heighten the risk that the Phase III results will not meet market expectations, undermining the company’s valuation.
The company’s financial statements indicate an upward trend in R&D expenses that is likely to continue, and while the cash balance extends through 2027, the company has not disclosed a clear contingency plan for a delayed Phase III readout or for potential regulatory setbacks. The incremental capital requirements associated with both the HCV and hepatitis E programs could strain cash reserves if the company must extend trial timelines or undertake additional safety studies, potentially necessitating new debt or equity issuances that would dilute shareholders. The absence of a current strategic partner or licensing agreement for the HCV regimen raises the question of whether Atea will be able to secure favorable reimbursement terms or pricing in a highly competitive therapeutic landscape dominated by established payers and generics. A negative Phase III outcome could also impede the company’s ability to attract future investment for its hepatitis E pipeline, further compromising its growth prospects. The combined effect of these financial and strategic uncertainties warrants a bearish view.
The company's emphasis on the lack of proton pump inhibitor interaction, while a useful differentiation, may overstate the clinical relevance of this factor given that many patients on HCV therapy already receive alternative acid‑reducing agents that do not interact with sofosbuvir or other DAAs. The real‑world impact of this differentiation may be limited, especially if the drug’s overall cost remains higher than existing therapies. Additionally, the company’s data on drug‑drug interactions have not been corroborated by independent third‑party studies, raising questions about the robustness of these findings. Consequently, the perceived advantage over Epclusa may not translate into significant market capture, particularly if payers focus on efficacy and safety rather than a single pharmacokinetic interaction. This potential overvaluation of the differentiation may lead to a slower adoption curve, thereby reducing the company’s revenue potential and supporting a bearish outlook.
Atea’s hepatitis E program, while theoretically lucrative, remains at an early preclinical stage, and the company has not yet demonstrated a clear path to regulatory approval or market entry for these candidates. The projected $500–$750 million per year revenue estimate is based on orphan drug pricing assumptions that may not be realized in practice, as payers could negotiate lower prices or challenge the orphan designation. The company’s current data set of 200‑fold potency over ribavirin is promising but does not guarantee clinical efficacy or safety, and the company has not yet performed any in‑vivo efficacy studies or established a therapeutic index. This lack of translational data heightens the risk that the hepatitis E pipeline will not generate the projected revenue, weakening the company’s overall valuation.
The company’s current share repurchase program, although signaling confidence, was conducted at a relatively low average price, but this does not offset the broader concern that the stock may be trading at a premium relative to intrinsic value if the Phase III program fails. Moreover, the repurchase program’s impact on free cash flow is limited, given the magnitude of the company’s ongoing R&D spend. Investors may interpret the share buyback as a short‑term management tactic rather than a meaningful long‑term value creation strategy. If the company’s Phase III outcome does not result in regulatory approval, the share price may decline sharply, eroding the gains from the repurchase program and potentially triggering a broader market sell‑off. This scenario supports a bearish perspective on the stock’s future performance.

Counterparty Name Breakdown of Revenue (2021)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	QNTM	Quantum Biopharma Ltd.	1,388,523.32 Bn	1.04	-	-
2	ATHE	Alterity Therapeutics Ltd	792,048.14 Bn	-	-	-
3	LEGN	Legend Biotech Corp	2,818.00 Bn	0.00	2,739.27	0.32 Bn
4	NBTX	Nanobiotix S.A.	2,403.58 Bn	-76.44	71,767.86	0.11 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	109.17 Bn	25.26	8.94	-
6	REGN	Regeneron Pharmaceuticals, Inc.	67.49 Bn	15.25	4.52	1.99 Bn
7	EVAX	Evaxion A/S	63.84 Bn	-5,893.63	8,479.11	-
8	ALNY	Alnylam Pharmaceuticals, Inc.	39.68 Bn	78.78	9.26	-

Research Tools

Developers

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

About

Investment thesis

Bull case

Bear case

Counterparty Name Breakdown of Revenue (2021)

Peer comparison

Research Tools

Developers

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

About

Investment thesis

Bull case

Bear case

Counterparty Name Breakdown of Revenue (2021)

Peer comparison

Create an account

Sign In

Reset Password